French Cost-Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time

French Cost-Effectiveness Trial ofFrench Cost-Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time PR Newswire MOUNTAIN VIEW, California, Oct. 28, 2013 PneumRx, Inc. (www.pneumrx.com), a leader in the field of interventional pulmonology, today announced that enrollment in the REVOLENS Study, a cost-effectiveness study of the PneumRx RePneu Lung Volume Reduction Coil (RePneu LVRC) in France, has been completed. The REVOLENS study was submitted last year to the French Ministry of Health by Professors Gaetan Deslee of the University Hospital of Reims and Charles- Hugo Marquette of the University Hospital of Nice and was accepted and funded by the Ministry of Health under the soutien aux techniques innovantes couteuses (STIC) program. The STIC program provides government funding for innovative medical technologies that have been validated by prior clinical studies, with a view toward establishing reimbursement for new devices. It was anticipated that the study, which began enrolling subjects in March 2013, would take 12 months to enroll all 100 subjects. Instead, enrollment was completed in less than 7 months. This rapid enrollment, which is rare among STIC trials, underscores the need for, and interest in, innovative, minimally invasive treatment options for patients with severe emphysema.